Matias E Valsecchi

Summary

Publications

  1. doi request reprint Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors
    Matias E Valsecchi
    Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA
    Clin Breast Cancer 9:225-30. 2009
  2. ncbi request reprint [A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity]
    Matias Valsecchi
    Laboratorio de Biología y Patología Molecular Universidad de Buenos Aires, Argentina
    Medicina (B Aires) 67:57-60. 2007
  3. doi request reprint Modifiable factors that influence colon cancer lymph node sampling and examination
    Matias E Valsecchi
    Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA
    Clin Colorectal Cancer 9:162-7. 2010
  4. doi request reprint Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
    Matias E Valsecchi
    Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Cancer 118:3484-93. 2012
  5. doi request reprint Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
    Matias E Valsecchi
    Departments of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Melanoma Res 23:33-9. 2013
  6. doi request reprint RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer
    Agnieszka K Witkiewicz
    Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 18:5110-22. 2012
  7. pmc Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
    Matias E Valsecchi
    Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    BMC Cancer 12:104. 2012
  8. doi request reprint Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis
    Matias E Valsecchi
    Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 29:1479-87. 2011

Detail Information

Publications8

  1. doi request reprint Reduced risk of bone metastasis for patients with breast cancer who use COX-2 inhibitors
    Matias E Valsecchi
    Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA 19141, USA
    Clin Breast Cancer 9:225-30. 2009
    ..We hypothesize that the use of cyclooxygenase (COX)-2 inhibitors in early disease phases could protect against the development of bony metastases...
  2. ncbi request reprint [A prevalent genetic variety of UDP-glycuronosyl transferase predicts high risk of irinotecan toxicity]
    Matias Valsecchi
    Laboratorio de Biología y Patología Molecular Universidad de Buenos Aires, Argentina
    Medicina (B Aires) 67:57-60. 2007
    ..This case is an example of the clinical applicability and the utility of the test as a toxicity predictor. We also discuss the clinical decisions that may be taken with these patients...
  3. doi request reprint Modifiable factors that influence colon cancer lymph node sampling and examination
    Matias E Valsecchi
    Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA, USA
    Clin Colorectal Cancer 9:162-7. 2010
    ..However, this standard of care is not always achieved. The objective of this study was to identify potential modifiable factors that may explain this inadequacy between the optimal approach and routine practice...
  4. doi request reprint Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma
    Matias E Valsecchi
    Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA
    Cancer 118:3484-93. 2012
    ....
  5. doi request reprint Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma
    Matias E Valsecchi
    Departments of Medical Oncology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA
    Melanoma Res 23:33-9. 2013
    ..Therapeutic approaches targeting SSTR might be beneficial in patients with metastatic uveal melanoma...
  6. doi request reprint RB-pathway disruption is associated with improved response to neoadjuvant chemotherapy in breast cancer
    Agnieszka K Witkiewicz
    Department of Pathology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    Clin Cancer Res 18:5110-22. 2012
    ..We sought to determine whether dysregulation of the retinoblastoma (RB) tumor suppressor pathway was associated with improved response to neoadjuvant chemotherapy in breast cancer...
  7. pmc Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?
    Matias E Valsecchi
    Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA 19107, USA
    BMC Cancer 12:104. 2012
    ..RRM1 and ERCC1 overexpression has been extensively investigated as potential predictive markers of tumor sensitivity to conventional chemotherapy agents, most thoroughly in lung cancer. However, data in pancreatic cancer are scarce...
  8. doi request reprint Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta-analysis
    Matias E Valsecchi
    Thomas Jefferson University, Philadelphia, PA, USA
    J Clin Oncol 29:1479-87. 2011
    ..To perform a meta-analysis of all published studies of sentinel lymph node (SLN) biopsy for staging patients with melanoma...